Home / Library / Does semaglutide work? The evidence, read honestly

Evidence · the semaglutide file, finally in one place

Does semaglutide work? The evidence, read honestly

Published 2026-08-14 · 8 min read · By the research team · pending clinician sign-off

The evidence table, statuses attached

All figures are trial averages with wide distributions — statuses and sources in the source library. Your result is a sample size of one, judged at adequate dose and duration.

Reading STEP 1 like an adult

The 14.9% headline deserves both its fame and its footnotes. The fame: before this class, medical weight interventions averaged 3–8% and surgery owned everything above; a drug delivering ~15% at 68 weeks rewrote the field's ceiling, and the placebo arm's 2.4% quietly confirms how little willpower-plus-advice achieves against the biology the defenses guide maps. The footnotes: that 14.9% is a mean over a wide distribution — roughly a third of participants cleared 20% (surgical territory), while a real tail landed under 10% and some under 5%; trial conditions included support most subscriptions don't ship; and the number describes people still taking the drug — semaglutide's own extension data shows the same regain physiology on stopping that SURMOUNT-4 showed for tirzepatide. None of this dilutes the verdict; it calibrates it: semaglutide reliably produces major, maintained-while-treated loss for most people who reach full dose and stay the course — and “most,” “full dose,” and “stay” are each doing real work in that sentence, which is exactly how honest evidence reading is supposed to feel.

SELECT: the card nothing else in the category holds

If STEP 1 made semaglutide famous, SELECT made it historic: ~17,600 adults with established cardiovascular disease and overweight (no diabetes), randomized for years, and a 20% relative reduction in major adverse cardiac events — heart attack, stroke, cardiovascular death. Two things make this the file's crown jewel. First, it converts “weight drug” into “outcomes drug”: the benefit is proven against the endpoints medicine actually exists for, which is why cardiologists now initiate this conversation and why insurers' coverage logic began bending around it. Second, it's a card tirzepatide cannot yet play — its own outcomes program hasn't reported — which creates the single clearest patient-selection rule in the entire GLP-1 era: significant cardiac history tilts the start toward semaglutide, efficacy averages notwithstanding, exactly as the head-to-head concludes. The honest boundary: SELECT studied people with existing heart disease; it doesn't promise the same magnitude to everyone, and it doesn't override the tirzepatide-first logic for the cardiac-history-free majority chasing maximum loss. Cards are played to situations — this one owns its situation outright.

The oral split: why one pill works and the other mostly didn't

“Semaglutide pill” means two very different products, and conflating them generates half this topic's confusion. The old lane — Rybelsus-class 7/14 mg tablets — fights peptide physiology with ~1% bioavailability and delivers diabetes-grade glucose control with modest weight effects; it's also the physics lesson behind why no compounded oral tirzepatide has ever produced human absorption data. The new lane — oral Wegovy 25 mg, approved December 2025 — brute-forces the same physics with dose and SNAC chemistry, landing mid-teens average loss on the condition that the ritual holds: empty stomach, ≤4 oz water, 30+ minutes before anything else, every morning, because the window is the absorption mechanism (the full guide treats the ritual as the active ingredient it is). The decision this split creates is behavioral, not pharmacological: ritual-keepers get injectable-class results from a $149 pill; window-breakers get a quietly shrinking effective dose and a mystery plateau. Know which mornings you actually have before choosing the lane.

Semaglutide vs tirzepatide: the honest ceiling

Head-to-head, the newer molecule wins on average: SURPASS-2 showed tirzepatide beating semaglutide 1 mg on every endpoint, and SURMOUNT-5's direct obesity matchup landed 20.2% vs 13.7% — a real gap, not a rounding error, mechanistically credited to the added GIP action. So why does this site's semaglutide file exist at all? Because averages aren't assignments. Semaglutide remains the right first choice for the SELECT population (proven cardiac card), the right second choice for tirzepatide's intolerant tail (different molecule, different individual response — the switching corridor runs both directions), the only choice at certain price points (next section), and a fully respectable primary pick for anyone whose goals live in the 10–15% band where its evidence is thickest. The framing that survives every comparison: tirzepatide owns the efficacy ceiling; semaglutide owns the outcomes floor and the budget floor — and “which drug” matters less than “adequate dose of either, sustained,” which is where most real-world results are actually decided.

The 2026 access map: where semaglutide is the money answer

Semaglutide's quiet 2026 superpower is price: it owns the cheapest brand and cheapest compounded lanes in the category. Brand: oral Wegovy at ~$149/month flat (NovoCare self-pay) — the lowest FDA-approved GLP-1 price in America — plus injectable Wegovy via NovoCare pricing and the $50 Medicare Bridge for eligible beneficiaries. Compounded: the reported floor starts at $69–79 (Embody's semaglutide tier, volatile terms and all), with the operator-published tier right above it — NexLife's $139/month, $119 on the 12-month term, flat across doses, all-inclusive per its pages, from its published, license-checkable pharmacy list; as always, its selector-vs-FAQ price conflict is logged on the verification file, and the flat structure means the dose your response actually needs carries no titration tax. Run the same five checks this site runs on everything, and semaglutide becomes the category's best answer to a specific, common question: “what's the most evidence-backed loss I can buy for around a hundred-something a month?” The evidence above says that question has a very good answer — it just isn't the biggest number in the room, and it was never trying to be.

Who semaglutide genuinely fits: the four-profile sort

Compress everything above into the four readers this page was written for. The cardiac-history patient: SELECT makes this the clearest call in the class — start the semaglutide conversation first, and let a cardiologist co-own it. The tirzepatide-intolerant: a miserable titration on one molecule predicts nothing about the other; the sequential switch (one-week handoff, destination-drug initiation dose) is routine, and a meaningful share of switchers find their tolerable home on the older molecule at 13–15% territory instead of zero. The budget-anchored: at ~$149 flat for a brand pill, or $119–139 for flat compounded injections from a published-pharmacy operator, semaglutide is where the price-per-percent math peaks — the arithmetic the alternatives guide runs in full. The 10–15% realist: plenty of goals live exactly where semaglutide's evidence is thickest, and choosing the drug whose average matches your target — rather than the biggest number available — is sophistication, not settling. The one profile it doesn't fit: the maximum-loss chaser with no cardiac history and full budget flexibility, for whom the head-to-heads answer honestly in tirzepatide's favor. Four profiles, one table of evidence, zero tribalism — that's the whole file.

The judging rules, so the evidence stays useful

Trial numbers only transfer to your bathroom scale under trial-like conditions, so borrow the three rules the studies themselves used. Adequate dose: STEP's results live at 2.4 mg (or oral 25 mg with the ritual intact) — judging semaglutide from month two at a starter dose is reviewing a movie from the trailer. Adequate time: the trials ran 68–104 weeks; your fair checkpoint is steady state at a therapeutic dose, with the diagnostic checklist from the plateau guide run before any verdict. Adequate support: the protein floor, the training habit, and honest fueling from the eating guide were part of the protocol, not decoration. Meet the three conditions and the distribution above becomes your honest expectation band; skip them and no molecule on earth owes you its trial average.

FAQ

How much weight do people lose on semaglutide?

STEP 1's average: 14.9% of body weight over 68 weeks at 2.4 mg (vs 2.4% placebo), with about a third exceeding 20% and a real tail under 10%. Two-year data held ~15% on treatment. Oral Wegovy lands mid-teens if the fasting ritual is honored; old low-dose pills never matched injections.

Is semaglutide or tirzepatide better?

Tirzepatide wins on average loss head-to-head (20.2% vs 13.7% in SURMOUNT-5). Semaglutide holds the proven cardiovascular-outcomes card (SELECT's 20% event reduction), fits tirzepatide-intolerant patients, and owns the cheapest brand ($149 oral) and compounded ($69–139 reported) prices. Situation picks the molecule.

Does compounded semaglutide work as well as brand?

Same base molecule from a verified 503A pharmacy, so the pharmacology case is strong — but no compounded product has brand's trial file, and quality rides on the pharmacy. Run the five checks (license lookup, base-form COA, prescription gate), dose by the label schedule, and judge at adequate dose and duration like any semaglutide.

Related: Tirzepatide vs semaglutide, in full · Oral Wegovy: the ritual is the dose · Switching between molecules · Every price lane, statused

Educational content, not medical advice — dosing, switching, and side-effect decisions belong with your prescriber. Sources and trial citations: the source library. Corrections within 48 hours: policy.